HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.

Abstract
Prostate cancer (CaP) is a major health problem in males in Western countries. Current therapeutic approaches are limited and many patients die of secondary disease (metastases). There is no cure for metastatic castration-resistant prostate cancer (CRPC). Targeting tumor-associated antigens is fast emerging as an area of promise to treat late stage and recurrent CaP. Extracellular matrix metalloproteinase inducer, EMMPRIN (CD147) is a multifunctional glycoprotein that can modify the tumor microenvironment by activating proteinases, inducing angiogenic factors in tumor and stromal cells, and regulating growth and survival of anchorage-independent tumor cells (micrometastases) and multidrug resistance (MDR). CD44 is a multifunctional protein involved in cell adhesion, migration and drug resistance, and is a primary receptor for hyaluronan (HA), a major component of the extracellular matrix (ECM) with a critical role in cell signaling and cell-ECM interactions in cancer. Our recent studies indicate both CD147 and CD44 are involved in cancer drug resistance and play very important roles in CaP metastasis. Thus, CD147 and CD44 may be ideal therapeutic targets to control metastatic and CRPC disease. This review will discuss their putative roles in CaP metastasis and MDR, and give an overview of literature regarding their expression on human CaP tissues. Additional focus will be on the potential of therapeutic strategies targeting CD147 and CD44 to prevent CaP metastasis and overcome drug resistance.
AuthorsJ L Hao, P J Cozzi, A Khatri, C A Power, Y Li
JournalCurrent cancer drug targets (Curr Cancer Drug Targets) Vol. 10 Issue 3 Pg. 287-306 (May 2010) ISSN: 1873-5576 [Electronic] Netherlands
PMID20370680 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • BSG protein, human
  • Biomarkers, Tumor
  • CD44 protein, human
  • Hyaluronan Receptors
  • Monocarboxylic Acid Transporters
  • Basigin
  • Hyaluronic Acid
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Basigin (genetics, metabolism)
  • Biomarkers, Tumor (genetics, metabolism)
  • Cell Adhesion
  • Cell Movement
  • Drug Resistance, Neoplasm
  • Genetic Therapy
  • Humans
  • Hyaluronan Receptors (genetics, metabolism)
  • Hyaluronic Acid (metabolism)
  • Immunotherapy
  • Male
  • Monocarboxylic Acid Transporters (metabolism)
  • Neoplasm Invasiveness
  • Neoplastic Stem Cells (immunology, pathology)
  • Neovascularization, Pathologic (genetics, immunology, prevention & control)
  • Prostatic Neoplasms (blood supply, genetics, immunology, secondary, therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: